The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma
Wael A. Harb, Nehal Lakhani, Ana Logsdon et al.
Key Points:
PNT2258 single-strandedphosphodiester DNA oligonucleotide encapsulated in specialized liposome that demonstrated antitumor activity
They block transcription of BCL2 through DNA interference (DNAi)
Multi-center, single-agent, pilot Phase II study, PNT2258 administered at dose of 120 mg/m2 as 3-hour IV infusion on days 1-5 of a 21-day cycle for six cycles or until progressive disease or unacceptable toxicity for relapsed and refractory NHL
1 patient for CLL has SD and 1 patient has progression of disease
Implications:
- PNT2258 first to target regulatory upstream region of BCL2 gene, which showed significant activity in relapsed NHL patients
View the original abstract on the ASH website.
